secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2023-06-29T23:59:59+00:00
Accession:  0001193125-23-178569
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma urges shareholders to vote FOR Infinity merger ahead of July 14 special meeting
--------------------------------------------------------------------------------

- Board reiterates recommendation to approve merger with Infinity Pharmaceuticals (INFI) at July 14 special meeting.
- Combined pipeline includes three clinical-stage programs: eganelisib, voruciclib (with Venclexta), and ME-344 (with Avastin).
- Key data expected from voruciclib and ME-344 by year-end 2023; eganelisib is a Phase 2 first-in-class PI3K-gamma inhibitor.
- Combined company will have experienced drug development team and is positioned to advance diversified oncology pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523178569/0001193125-23-178569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523178569/d461231d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-178569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer